Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability.

about

Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability.

Item

http://www.wikidata.org/entity/Q46871428

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Transdermal agomelatine microe ...... n and in vivo bioavailability.

@en

Transdermal agomelatine microe ...... n and in vivo bioavailability.

@nl

type

Item

label

Transdermal agomelatine microe ...... n and in vivo bioavailability.

@en

Transdermal agomelatine microe ...... n and in vivo bioavailability.

@nl

prefLabel

Transdermal agomelatine microe ...... n and in vivo bioavailability.

@en

Transdermal agomelatine microe ...... n and in vivo bioavailability.

@nl

P1476

Transdermal agomelatine microe ...... n and in vivo bioavailability.

@en

P2093

Ahmed A Aboelwafa

http://www.w3.org/2001/XMLSchema#string

Ahmed H Elshafeey

http://www.w3.org/2001/XMLSchema#string

Mayada Said

http://www.w3.org/2001/XMLSchema#string

P2860

The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways

Pharmacotherapy of depression: a historical analysis

Dose translation from animal to human studies revisited

Drug distribution in human skin using two different in vitro test systems: comparison with in vivo data.

Preparation, evaluation, and NMR characterization of vinpocetine microemulsion for transdermal delivery.

Phosphatidylcholine embedded microemulsions: physical properties and improved Caco-2 cell permeability.

Design and evaluation of microemulsions for improved parenteral delivery of propofol.

An association study of the m6A genes with major depressive disorder in Chinese Han population.

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.

P304

1159-1169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10717544.2017.1365392

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ibrahim Elsayed

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28831842

http://www.w3.org/2001/XMLSchema#string

P921

Amar